Skip to main content

Table 3 Baseline CSF biomarkers of PD stratified by RBD

From: CSF Aβ1–42 level is associated with cognitive decline in early Parkinson’s disease with rapid eye movement sleep behavior disorder

  PD with RBD PD without RBD P value
  (N = 136) (N = 214)
1–42 (pg/ml) 354.70 ± 103.45 384.73 ± 90.77 0.005*
t-tau (pg/ml) 43.76 ± 18.75 44.42 ± 16.89 0.736
p-tau (pg/ml) 14.57 ± 7.85 16.31 ± 11.32 0.121
alpha-synuclein (pg/ml) 1811.69 ± 741.35 1860.50 ± 818.55 0.578
p-tau/t-tau 0.35 ± 0.17 0.39 ± 0.25 0.130
t-tau/Aβ1–42 0.13 ± 0.07 0.12 ± 0.05 0.056
  1. Results are mean ± (SD). P value was assessed using two-tailed Student t test for each variable. *P value statistically significant. The PD with RBD patients had significantly lower contents of CSF Aβ1–42
  2. Abbreviations: PD Parkinsonr’s disease, RBD Rapid eye movement sleep behavioral disorder, CSF cerebrospinal fluid, t-tau total tau, p-tau phosphorylated-tau, β-amyloid